| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6170156 | The Breast | 2013 | 7 Pages |
Abstract
This study confirms that integrating anti-HER2 therapy in primary treatment for HER2 positive breast cancer is active. NPLD is a safe option to minimize cardiotoxicity.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
S. Saracchini, L. Foltran, F. Tuccia, A. Bassini, S. Sulfaro, E. Micheli, A. Del Conte, M. Bertola, M. Gion, M. Lorenzon, S. Tumolo,